Introduction
============

Increasing evidence proves the significant efficacy of immune checkpoint inhibitors (ICIs) in treatment of advanced cancers [@B1]-[@B4]. ICIs targeting the programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) pathway significantly improve the progression-free survival and overall survival compared with standard chemotherapy, so PD-1/PDL1 antibodies are currently approved for treatment of various malignancies [@B5]-[@B11]. Since the anti-PD-1 antibody pembrolizumab was approved in September 2014 for treatment of advanced melanoma, the clinical development of PD-1/PD-L1 inhibitors as anticancer drugs has been widely expanded. Currently, the Food and Drug Administration has approved PD-1/PD-L1 inhibitors for treatment of 9 types of cancers. For instance, pembrolizumab can be used to treat melanoma [@B2], [@B12]-[@B14], non-small cell lung cancer (NSCLC) [@B7], [@B15]-[@B19], head and neck squamous cell carcinoma (HNSCC) [@B20], Hodgkin\'s lymphoma [@B21], urothelial cancer [@B22], [@B23] and gastric cancer [@B24]. Anti-PD-1 antibody nivolumab is recommended for treating melanoma [@B11], [@B25], renal cell carcinoma (RCC)[@B26], Hodgkin\'s lymphoma [@B27], [@B28], urine epidermal cancer [@B29], MSI-H colon cancer [@B30] and hepatocellular carcinoma [@B31]. Anti-PD-L1 antibody atezolizumab is suggested for treatment of urothelial cancer [@B22], [@B32] and NSCLC [@B6], [@B33], and anti-PD-L1 antibodies avelumab and durvalumab can be used to treat urothelial cancer[@B34], [@B35]. Compared with cytotoxic chemotherapy, ICIs have unique toxicity based on their action mechanism, which is considered to be immune-related adverse event (IRAE) [@B36]-[@B39]. Inhibiting the PD-1/PD-L1 pathway may lead to autoimmune toxicity, some of which may be severe or even life- threatening [@B36], [@B40].

Diarrhea is a common side effect of cancer treatment that, in severe cases, can lead to death or to patients having to stop lifesaving treatment because often there are no effective therapies to control the diarrhea. Diarrhea in cancer patients can quickly lead to life-threatening consequences such as dehydration, electrolyte imbalance, shock, etc. Compared to chemotherapy-related diarrhea the immunological preparation of PD-1/PD-L1 is prone to cause autoimmune digestive diseases such as ulcerative colitis, and may also cause side effects of diarrhea.

Given the clinical efficacy evidence for a wide spectrum of tumor types, the PD-1 ICI therapy is expected to be increasingly used by oncologists as a monotherapy or in combination with other drugs. Therefore, physicians in cancer immunotherapy must be familiar with the pathogenesis of diarrhea in different tumors and different treatment regimens, and provide useful information to optimize the management of this toxicity. At present, there is no complete description about the clinical experience of anti-PD-1/PD-L1-associated diarrhea patients, or about the management and outcome of this toxicity. Therefore, we conducted a meta-analysis of PD-1 inhibitors in cancer patients and compared the incidence and severity of diarrhea among different tumor types, different treatment regimens.

1. Methods {#Section1}
==========

1.1. Literature selection and data extraction {#Section1.1}
---------------------------------------------

Two researchers (Lei Zhao and Huihui Li) independently reviewed the databases Medline, PMC database and EMBASE to select potential relevant articles. Any discrepancy between them was resolved by consensus. The following medical subject heading terms were used: PD-1, PDL1, CD274, programmed death receptor 1, programmed death receptor ligand, immune checkpoint inhibitor, nivolumab, BMS936558, pembrolizumab, MK-3475, MPDL3280A, atezolizumab, avelumab, MSB0010718C, durvalumab, and diarrhea. The databases were searched from the inception until December, 2018.

The inclusion criteria were: (a) phase I, II and III trials in cancer patients; (b) random assignment of participants to single PD-1/PD-L1 inhibitor treatment or other control therapy (e.g. ipilimumab, placebo); (c) reporting diarrhea events or event rate and sample size for any all-grade or high-grade (≥3) adverse events;(d) random controlled trial.

The following information was extracted by two independent reviewers (Lei Zhao and Huihui Li) from the included studies: first author, publication year, study name, clinical trial registration number, total number of patients, mean age, trial phase, treatment plan, tumor type, primary inclusion criteria, and numbers of patients with all grades and high-grade treatment-related diarrhea. The treatment regimens were classified as PD-1/PD-L1 inhibitor monotherapy, PD-1/PD-L1 inhibitor plus CTLA-4 inhibitor ipilimumab, chemotherapy, placebo, and ipilimumab. According to the different doses, monotherapy was divided into low-dose group and high-dose group.

1.2. Quality assessment {#Section1.2}
-----------------------

The two reviewers (Lei Zhao, Huihui Li) used the Jadad scoring method[@B41] to evaluate the quality of each included study from randomized (0 or 1), double-blind (0, 1 or 2), recorded loss of follow-up and/or exit (0 or 1) and assign hidden (0 or 1). A score ≥ 3 indicates high quality.

1.3. Statistical analysis {#Section1.3}
-------------------------

Meta-analysis for statistical analysis was performed using Stata12.1 (Stata Corp, College Station, TX, USA). Heterogeneity was analyzed by Q test, and I^2^\<25%, 25%-75%, and \>75% indicate mild, moderate and significant heterogeneity, respectively. In case of insignificant heterogeneity between studies indicated as P\>0.05, a fixed effect model was used; otherwise a random effect model was used. The incidence of diarrhea was evaluated by relative risk (RR) and 95% confidence interval (CI), and the analysis results were represented by forest maps. Two-tailed p \< 0.05 was considered significant. This meta-analysis has been registered on the PROSPERO website (Registration Number: CRD42018111834).

2. Results {#Section2}
==========

The database search initially returned 4021 studies. After screening and eligibility assessment, a total of 21 randomized controlled trials (RCTs, n=11554 patients) were identified for meta- analysis. ICIs tested in these studies included nivolumab (n=13 studies), pembrolizumab (n=6), avelumab (n=1) and durvalumab (n=1). Tumor types tested included NSCLC (n=7 studies), melanoma (n=10), HNSCC (n=1), Renal Cell Carcinoma (RCC) (n=1), gastric cancer (n=1) and small cell lung cancer (SCLC) (n=1). According to the clinical staging, 15, 5 and 1 of the 21 RCTs were at phase 3, 2 and 1, respectively (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

2.1. Risks of diarrhea among different treatment regimens {#Section2.1}
---------------------------------------------------------

### All-grade diarrhea

The risks of all-grade diarrhea in PD-1/PD-L1 inhibitors were compared among different treatment regimens: PD-1/PD-L1 inhibitor monotherapy versus PD-1/PD-L1 inhibitor plus ipilimumab, versus chemotherapy, versus placebo, versus ipilimumab, and high-dose versus low-dose in the 20 studies (Figure [2](#F2){ref-type="fig"}).

#### PD-1/PD-L1 inhibitor monotherapy versus placebo

Two RCTs [@B42], [@B43] compared PD-1/PD-L1 inhibitor monotherapy and placebo (n=1,720 patients). Classification based on tumor type included melanoma (n = 1 study) and NSCLC (n = 1). Classification according to the use of ICIs included pembrolizumab (n = 1) and durvalumab (n = 1). The pooled RR of all-grade diarrhea incidence was not significant after PD-1/PD-L1 inhibitor monotherapy (RR 1.07, 95%CI: 0.87-1.32, P=0.516) (Figure [2](#F2){ref-type="fig"}A).

#### PD-1/PD-L1 inhibitor monotherapy versus chemotherapy

Eleven RCTs [@B5], [@B7], [@B11], [@B12], [@B18], [@B44]-[@B49] compared PD-1/PD-L1 inhibitor monotherapy and conventional chemotherapy (n=5,915 patients). Classification according to tumor type included melanoma (n = 3 study), HNSCC (n=1), Gastric cancer (n=1) and NSCLC (n = 6). Classification according to the use of ICIs included nivolumab (n = 7 study), pembrolizumab (n = 3) and Avelumab (n=1). The risk of all-grade diarrhea after PD-1/PD-L1 inhibitor monotherapy was significantly decreased (RR 0.69, 95%CI: 0.49-0.98, P=0.037; Figure [2](#F2){ref-type="fig"}B). The risk of all-grade diarrhea after PD-1/PD-L1 inhibitor monotherapy in Carcinoma of the Head and Neck and Gastric cancer patients were significantly decreased (RR 0.50, 95%CI: 0.26-0.98, P=0.043; RR 0.23, 95%CI: 0.12-0.42, P=0.000 Figure [2](#F2){ref-type="fig"}B).

#### PD-1/PD-L1 inhibitor monotherapy versus ipilimumab

Three RCTs [@B13], [@B50], [@B51] compared PD-1/PD-L1 inhibitor monotherapy and ipilimumab (n=2,596 patients). The tumor type was malignant melanoma. Classification according to the use of ICIs was nivolumab (n=2) and pembrolizumab (n=1). The study group of Caroline Robert 2015[@B13] was divided into two subgroups according to drug intervals and thus can be analyzed as two studies. The pooled RR of all-grade diarrhea incidence after the PD-1/PD-L1 inhibitor monotherapy (nivolumab or pembrolizumab) was significantly decreased (RR 0.60, 95%CI: 0.53-0.68, P=0.000; Figure [2](#F2){ref-type="fig"}C).

#### Nivolumab plus ipilimumab compared to nivolumab monotherapy

Four RCTs [@B42], [@B48], [@B50], [@B52] compared nivolumab plus ipilimumab and nivolumab monotherapy (n= 1,805 patients). Classification of tumor type was SCLC (n=1 study), NSCLC (n=1) and melanoma (n=2). Our meta-analysis reveals that nivolumab plus ipilimumab significantly increased the risk of all-grade diarrhea compared to nivolumab monotherapy (RR 1.90, 95%CI: 1.58-2.30, P=0.000; Figure [2](#F2){ref-type="fig"}D).

#### High-dose group versus low-dose group

Three RCTs [@B7], [@B26], [@B47] compared the low-dose and high-dose PD-1/PD-L1 inhibitor monotherapy (n= 1039 patients). Pembrolizumab 2 mg/kg is defined as low dose; 10 mg/kg is high-dose. Nivolumab ≤2 mg/kg is defined as low dose, 10 mg/kg is high-dose. Classification according to tumor type was melanoma (n = 1 study), RCC (n = 1) and NSCLC (n = 1). Results showed no significant risk in the high-dose group (RR 1.15, 95%CI: 0.80-1.67, P=0.446; Figure [2](#F2){ref-type="fig"}E).

### High-grade diarrhea

Figure [3](#F3){ref-type="fig"} showed the risk of high-grade (≥ 3) diarrhea according to different treatment regimens: PD-1/PD-L1 inhibitor monotherapy versus PD-1/PD-L1 inhibitor plus ipilimumab, versus chemotherapy, versus placebo, versus ipilimumab, and low-dose versus high-dose.

#### PD-1/PD-L1 inhibitor monotherapy versus placebo

Inclusion of the study and number of patient\'s high-grade diarrhea were consistent with previous all-grade diarrhea. As shown in Figure [3](#F3){ref-type="fig"}A, when compared with placebo, there was not a significant increase in the risk of high-grade diarrhea incidence for PD-1/PD-L1 inhibitor monotherapy (RR 0.85, 95%CI: 0.29-2.44, P=0.756).

#### PD-1/PD-L1 inhibitor monotherapy versus chemotherapy

Inclusion of the study and number of patient\'s high-grade diarrhea were consistent with previous all-grade diarrhea. Results showed a significant decreased in the risk of high-grade diarrhea after monotherapy (RR 0.50, 95%CI: 0.26-0.95, P = 0.035; Figure [3](#F3){ref-type="fig"}B). Of the 7 RCTs on non-small cell lung cancer, 5 were treated with nivolumab and 2 with pembrolizumab. The use of nivolumab or pembrolizumab seems to reduce the risk of diarrhea compared to chemotherapy, but the results are not significant (RR 0.58, 95%CI: 0.25-1.31, P = 0.190; RR 0.61, 95%CI: 0.03-13.01, P = 0.754, respectively).

#### PD-1/PD-L1 inhibitor monotherapy versus ipilimumab

Inclusion of the study and number of patients of high-grade diarrhea were consistent with previous grades of diarrhea. Results showed significantly decreased in the risk of high-grade diarrhea after PD-1/PD-L1 inhibitor monotherapy (RR 0.38, 95%CI: 0.18-0.79, P=0.009; Figure [3](#F3){ref-type="fig"}C). Our meta-analysis reveals that PD-1 antibodies (pembrolizumab or nivolumab) reduce the risk of severe diarrhea compared to ipilimumab.

#### Nivolumab plus ipilimumab compared to nivolumab monotherapy

Inclusion of the study and number of patients of high-grade diarrhea were consistent with previous grades of diarrhea. The tumor type was melanoma in all cases. Results showed no significant increase in the risk of high-grade diarrhea after nivolumab plus ipilimumab treatment (RR 3.29, 95%CI: 1.80-6.03, P=0.000; Figure [3](#F3){ref-type="fig"}E).

#### High-dose group versus low-dose group

Three RCTs [@B7], [@B12], [@B47] compared the High-dose and Low-dose treatments (n=1,212 patients). Classification of tumor type was melanoma (n=2 studies) and NSCLC (n=1). Results showed no significant increase in the risk of high-grade diarrhea after high-dose treatment (RR 1.86, 95%CI: 0.51-6.79, P=0.345; Figure [3](#F3){ref-type="fig"}F).

### Study quality and publication bias

Fifteen trials were open label, whereas five trials were double blind controlled. The Jadad score ranged from 3 to 4. For RR of all-grade between PD-1/PD-L1 inhibitor monotherapy and chemotherapy or high-grade diarrhea between the monotherapy and ipilimumab, the Egger test suggested some evidence of publication bias. No evidence of bias was found in other comparisons of Egger tests (all P\>0.05), or in all Begg tests (all P\>0.05).

3. Discussion {#Section3}
=============

Although an increasing number of clinical studies have confirmed the overall survival benefit of PD-1/PD-L1 inhibitors treatment, PD-1/PD-L1 inhibitors therapy increases the toxicity of the drug remains controversial, especially diarrhea. Our meta-analysis is the first large-scale analysis of different immunologic treatment regimens compared with chemotherapy or ipilimumab for the toxic side effects of diarrhea. In our research, the risk of all-grade diarrhea after the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination was 1.90 times higher than that of PD-1/PD-L1 inhibitors monotherapy (P\<0.05), and the risk was 0.72 and 0.60 times higher than that of chemotherapy and ipilimumab compared with monotherapy (P\<0.05). Chemotherapy is the most prone to diarrhea, followed by PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination, and finally PD-1/PD-L1 inhibitors monotherapy. When compared with placebo, we did not observe a significant increase in the risk of all-grade or severe diarrhea incidence, and our meta-analysis also reveals that high-dose PD-1/PD-L1 inhibitor monotherapy did not increase the risk of all-grade or severe diarrhea when compared with low-dose(all P\>0.05), which suggested that PD-1/PD-L1 inhibitor monotherapy is relatively safe. The risk of grade ≥ 3 diarrheas for PD-1/PD-L1 inhibitors alone significantly decreased than chemotherapy or ipilimumab, while the PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor combination significantly increase than monotherapy.

The basic principle of binding PD-1 / PD-L1 inhibitors and CTLA-4 inhibitors is that they have different mechanisms of action. Anti-CTLA-4 mainly acts on the lymph node area, restores the induction and proliferation of activated T cells, and resists PD-1 acts mainly on the periphery of the tumor site, preventing the tumor-infiltrating tumor-infiltrating PD-L1-expressing tumor and plasma-like dendritic cells from neutralizing cytotoxic T cells [@B53]. Our result found that patients taking CTLA-4 inhibitors ipilimumab had a significantly higher risk of developing diarrhea than those using PD-1 / PD-L1 inhibitors. This is likely to be related to the different mechanisms of action of the two drugs. Although the combination of PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor has achieved good efficacy [@B25], [@B50], [@B52], the corresponding toxic side effects of combination therapy, especially diarrhea, are significantly higher than those of PD-1/PD-L1 inhibitors alone. Combination therapy with both CTLA-4 and PD-1 blockers raised the risk of GI toxicities to about 45% which is much higher than monotherapy [@B54]. The risk of diarrhea was significantly different compared to the use of PD-1/PD-L1 inhibitors alone and chemotherapy in different tumor types. In patients with NSCLC patients, the risk of diarrhea using PD-1 / PD-L1 inhibitors monotherapy is significantly lower than that of patients receiving chemotherapy. However, this result did not find in melanoma patients. Our results show that patients taking pembrolizumab or nivolumab have a slightly different risk of all-grade diarrhea compared with chemotherapy [@B11], [@B12], [@B47]. Furthermore, our study demonstrates no significant difference in the incidence of diarrhea between low-dose versus high-dose PD-1/PD-L1 inhibitors, which are consistent with another study [@B12]. This provides reliable evidence for further exploration of adjusting drug doses in future clinical trial design and clinical practice.

As far as we know, this is the systematic review including the largest number of RCTs for analysis of immune-related diarrhea. The present study has some limitations. Firstly, these relevant studies have applied PD-1/PD-L1 inhibitors to different treatment lines, and there may be inconsistencies in the underlying characteristics of the patients. Secondly, since the present study is based on a secondary analysis of the final results of each report, we were unable to obtain patient-level disease characteristics and variables, or to determine the specific risk factors associated with the development of immune-related diarrhea. Thirdly, our results were influenced by the limitations of individual clinical trial design. Some of the clinical trials included in the meta- analysis were open label, which may lead to subjective bias. Finally, clinical RCTs included in the meta-analysis had strict inclusion and exclusion criteria. The patients selected in the study were with good PS, but in clinical practice, a large number of patients suffered impaired organ dysfunction and/or functional status and may have a higher incidence of actual toxicity. In the future, large-sample RCTs are needed to compare the incidence and severity of PD-1/PD-L1 inhibitor associated diarrhea among more tumor types and among more combination regimens.

Overall, PD-1/PD-L1 inhibitors have a lower risk of developing diarrhea than chemotherapy and CTLA-4 inhibitor. There is no direct relationship between the dose of PD-1/PD-L1 inhibitors and the risk of developing diarrhea. This study provides reliable evidence for further exploring the combination of PD-1/PD-L1 inhibitors with other drugs in clinical trial design and clinical practice.
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###### 

Characteristics of Relevant Studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analysis Method                                   Source                                      Format                                                                         Data Set                                Tumor Type                                                                                                                  Main Inclusion Criterion                                                                                Treatment                    Sample Size    Age, Median(range),y   Jadad score
  ------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------- -------------- ---------------------- -------------
  Meta-analysis\                                    R.L.Ferris 2016 CheckMate 141 NCT02105636   Full text                                                                      Randomized, open-label, phase 3 trial   Head and neck                                                                                                               Recurrent squamous-cell carcinoma of the head and neck                                                  1\. Nivolumab 3 mg/kg Q2W\   240\           59(29-83)\             3
  Meta-analysis                                                                                                                                                                                                                                                                                                                                                                                                                                            2. Standard therapy          121            61(28-78)              

  Julie Brahmer 2015 CheckMate 017 NCT01642004      Full text                                   Randomized, open-label, international, phase 3 study                           NSCLC                                   Stage IIIB or IV squamous-cell NSCLC                                                                                        1\. Nivolumab 3 mg/kg Q2W\                                                                              135\                         62 (39-85)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Docetaxel 75 mg/m2 Q3W                                                                               137                          64 (42-84)                            

  Caroline Robert 2015 KEYNOTE-006 NCT01866319      Full text                                   Randomized, controlled, phase 3 study                                          Melanoma                                Unresectable stage III or IV melanoma                                                                                       1\. Pembrolizumab 10 mg/kg Q2W\                                                                         279\                         61 (18-89)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Pembrolizumab 10 mg/kg Q3W\                                                                          277\                         63 (22-89)\                           
                                                                                                                                                                                                                                                                                                                                                   3. Ipilimumab 3 mg/kg Q3W                                                                               278                          62 (18-88)                            

  Omid Hamid 2017 KEYNOTE-002 NCT01704287           Full text                                   Randomised, open-label, phase 2 study                                          Melanoma                                Unresectable stage III or stage IV melanoma not amenable to local therapy                                                   1\. Pembrolizumab 2 mg/kg Q3W\                                                                          180\                         62 (15-87)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Pembrolizumab 10 mg/kg Q3W\                                                                          181\                         60 (27-89)\                           
                                                                                                                                                                                                                                                                                                                                                   3. Chemotherapy(carboplatin\                                                                            179                          63 (27-87)                            
                                                                                                                                                                                                                                                                                                                                                   , carboplatin plus paclitaxel, dacarbazine, paclitaxel alone or oral temozolomide)                                                                                         

  J.D. Wolchok 2017 CheckMate 067 NCT01844505       Full text                                   Double-blind, Randomised, phase 3 trial                                        Melanoma                                Stage III (unresectable) or stage IV melanoma                                                                               1.Nivolumab 1 mg/kg Q3W plus ipilimumab 3 mg /kg Q3W for four doses,followed by nivolumab 3mg/kg Q2W\   314\                         61 (18‒88)\    4                      
                                                                                                                                                                                                                                                                                                                                                   2.Nivolumab 3 mg/kg Q2W\                                                                                316\                         60 (25‒90)\                           
                                                                                                                                                                                                                                                                                                                                                   3.Ipilimumab 3 mg/kg Q3W for four doses                                                                 315                          62 (18‒89)                            

  Michael A. Postow 2015NCT01927419                 Full text                                   Randomized 2:1 in a double-blinded phase 2 trial                               Melanoma                                Unresectable, previously-untreated, stage III or IV melanoma with measurable disease                                        1\. Nivolumab 1mg/kg Q3W plus ipilimumab 3mg/kg first 4 doses,then nivolumab 3mg/kg Q2W\                95\                          64 (27- 87)\   4                      
                                                                                                                                                                                                                                                                                                                                                   2.Ipilimumab 3mg/kg first 4 doses                                                                       47                           67 (31- 80)                           

  Georgina V Long 2018NCT02374242                   Full text                                   Multicentre, open-label randomised, phase 2 trial                              Melanoma                                Melanoma brain metastases                                                                                                   1\. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg Q3W for four doses; then nivolumab 3 mg/kg Q2W\              35\                          59 (53-68)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Nivolumab 3 mg/kg Q2W\                                                                               25\                          63 (52-74)\                           
                                                                                                                                                                                                                                                                                                                                                   3. Nivolumab 3 mg/kg Q2W( brain metastases)                                                             16                           51 (48-56)                            

  Caroline Robert, 2014KEYNOTE-001 NCT01295827      Full text                                   Open-label, international, multicentre phase 1 trial                           Melanoma                                Progressive, measurable, unresectable melanoma                                                                              1.Pembrolizumab 2 mg/kg Q3W\                                                                            89\                          57 (18-88)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2.Pembrolizumab 10 mg/kg Q3W                                                                            84                           60.7 (27-86)                          

  Alexander M.M. Eggermont 2018 NCT02362594         Full text                                   Randomized, double-blind phase 3 trial                                         Melanoma                                Resected stage III melanoma                                                                                                 1\. Pembrolizumab 200 mg Q3W for 18 doses\                                                              514\                         54 (19-88)\    4                      
                                                                                                                                                                                                                                                                                                                                                   2. Placebo                                                                                              505                          54 (19-83)                            

  S.J.Antonia 2017 PACIFIC NCT02125461              Full text                                   Global, randomized, phase 3 trial                                              NSCLC                                   Stage III, locally advanced, unresectableNSCLC                                                                              1\. Durvalumab10 mg/kg Q2W for up to 12 months.\                                                        476\                         64(31-84)\     3                      
                                                                                                                                                                                                                                                                                                                                                   2. Placebo                                                                                              237                          64(23-90)                             

  Martin Reck 2016 KEYNOTE-024 NCT02142738          Full text                                   Open-label, randomised , phase 3 trial                                         NSCLC                                   Untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells kinase gene                                   1\. Pembrolizumab 200 mg Q3W for 35 cycles\                                                             154\                         64.5(33-90)\   3                      
                                                                                                                                                                                                                                                                                                                                                   2.Investigator\'s choice of platinum based chemotherapy for 4 to 6 cycles                               151                          66(38-85)                             

  D.P. Carbone 2017 CheckMate 026 NCT02041533       Full text                                   Open-label randomized phase 3 trial                                            NSCLC                                   Untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more                                      1\. Nivolumab 3 mg/kg Q2W\                                                                              271\                         63(32-89)\     3                      
                                                                                                                                                                                                                                                                                                                                                   2. Platinum-based chemotherapy Q3W for up to six cycles                                                 270                          65(29-87)                             

  Roy S Herbst 2016 KEYNOTE-010 NCT01905657         Full text                                   Randomised, open-label, phase 2/3 study                                        NSCLC                                   Previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells                          1\. Pembrolizumab 2 mg/kg Q3W\                                                                          344\                         63 (56-69)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Pembrolizumab 10 mg/kg Q3W\                                                                          346\                         63 (56-69)\                           
                                                                                                                                                                                                                                                                                                                                                   3. Docetaxel 75 mg/m² Q3W                                                                               343                          62 (56-69)                            

  Scott J Antonia 2016 CheckMate 032 NCT01928394    Full text                                   Randomised,Cohort of this phase 1/2 multicentre, multi-arm, open-label trial   Recurrent small-cell lung cancer        Limited-stage orextensive-stage SCLC, and had disease progression after at least one previous platinum-containing regimen   1\. Nivolumab 3 mg/kg Q2W\                                                                              98\                          63 (57-68)\    3                      
                                                                                                                                                                                                                                                                                                                                                   2. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W for four cycles, nivolumab3 mg/kg Q2W\                 61\                          66 (58-71)\                           
                                                                                                                                                                                                                                                                                                                                                   3. Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for four cycles, nivolumab3 mg/kg Q2W                  54                           61 (56-65)                            

  M.D. Hellmann 2018 CheckMate 227 NCT02477826      Full text                                   Randomised,Multipart, open-label phase 3 trial                                 stage IV or recurrent NSCLC             stage IV or recurrent NSCLC that was not previously treated with chemotherapy                                               1\. Nivolumab 3 mg/kg Q2W plus Ipilimumab 1 mg/kg Q6W\                                                  576\                         \-             3                      
                                                                                                                                                                                                                                                                                                                                                   2. Nivolumab 240 mg Q2W\                                                                                391\                                                               
                                                                                                                                                                                                                                                                                                                                                   3. Chemotherapy                                                                                         570                                                                

  Hossein Borghaei 2015 CheckMate 057 NCT01673867   Full text                                   Randomised, phase 3 study                                                      Non-squamous NSCLC                      stage IIIB/IV or recurrent non-squamous NSCLC                                                                               1\. Nivolumab 3 mg/kg Q2W\                                                                              292\                         61(37-84)\     3                      
                                                                                                                                                                                                                                                                                                                                                   2. Docetaxel 75 mg/m2 Q3W                                                                               290                          64(21-85)                             

  Jeffrey S Weber 2015 CheckMate 037 NCT01721746    Full text                                   Randomised, controlled, open-label, phase 3 trial                              melanoma                                unresectable or metastatic melanoma, and progressed after ipilimumab, or\                                                   1\. Nivolumab 3 mg/kg Q2W\                                                                              272\                         59 (23-88)\    3                      
                                                                                                                                                                                                                       ipilimumab and a BRAF inhibitor if they were *BRAF*V^600^ mutation-positive                                                 2. ICC(dacarbazine 1000 mg/m^2^ Q3W; carboplatin area under the curve 6+ paclitaxel 175 mg/m^2^ Q3W)    133                          62 (29-85)                            

  Caroline Robert 2014 CheckMate 066 NCT01721772    Full text                                   Randomised, double-blind, phase 3 trial                                        Melanoma                                unresectable, previously untreated stage III or IV melanoma without a BRAF mutation                                         1\. Nivolumab(3 mg/kg Q2W)+ placebo Q3W\                                                                210\                         64 (18-86)\    4                      
                                                                                                                                                                                                                                                                                                                                                   2. Dacarbazine(1000 mg/ m2 Q3W)+ placebo Q2W                                                            208                          66 (26-87)                            

  J. Weber 2017 CheckMate 238 NCT02388906           Full text                                   Randomized, double-blind, phase 3 trial                                        Melanoma                                complete resection of stage IIIB,IIIC, or IV melanoma                                                                       1\. Nivolumab 3 mg/kg Q2W\                                                                              453\                         56 (19-83)\    4                      
                                                                                                                                                                                                                                                                                                                                                   2. Ipilimumab 10mg/kg Q3W for four doses                                                                453                          54 (18-86)                            

  Robert J. Motzer 2015 NCT01354431                 Full text                                   Blinded, randomized, multicenter phase II trial                                Renal Cell Carcinoma                    Metastatic Renal Cell Carcinoma                                                                                             1\. Nivolumab 0.3mg/kg Q3W\                                                                             60\                          61±9\          3                      
                                                                                                                                                                                                                                                                                                                                                   2. Nivolumab 2mg/kg Q3W\                                                                                54\                          61±8\                                 
                                                                                                                                                                                                                                                                                                                                                   3. Nivolumab 10 mg/kg Q3W                                                                               54                           61±10                                 

  Y.-J. Bang 2018 NCT02625623                       Full text                                   multicentre, international, randomised, open-label, phase III trial            gastric cancer                          metastatic gastric cancer/gastrooesophageal\                                                                                1\. Avelumab 10mg/kg Q2W\                                                                               185\                         59 (29-86)\    3                      
                                                                                                                                                                                                                       junction cancer                                                                                                             2. Physician\'s choice of chemotherapy                                                                  186                          61 (18-82)                            
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